Table 2.
Relationship Between Comorbidity and Clinical Outcomes
| Comorbidity Variable | Incident AE* |
Time to Relapse† |
Overall Survival† |
||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Total No. comorbid conditions | 0.97 | 0.86 to 1.09 | .60 | 1.09 | 0.95 to 1.26 | 0.23 | 1.18 | 1.06 to 1.33 | < .01 |
| Comorbidity burden score | 0.97 | 0.92 to 1.04 | .42 | 1.03 | 0.97 to 1.10 | 0.37 | 1.08 | 1.03 to 1.14 | < .01 |
Abbreviations: AE, adverse event; HR, hazard ratio; OR, odds ratio; AC, doxorubicin and cyclophosphamide; CMF, cyclophosphamide, methotrexate, fluorouracil.
*
Any grade 3, 4, or 5 AE.
†
Adjusted for age, tumor size, chemotherapy treatment arm (AC/CMF v capecitabine), nodal status, and hormone receptor status.